AGs Urge Congress to Allow DEA to Hold Drug Manufacturers and Distributors Accountable for Opioid Oversupply

44 Attorneys General Ask for Repeal of Law Regarding DEA Suspension Orders

WASHINGTON, D.C. – Attorney General Karl A. Racine is among 44 state and territorial attorneys general who joined a letter to congressional leaders urging them to repeal a 2016 federal law so registered drug manufacturers and distributors who have willfully contributed to the nation’s oversupply of opioids can be held accountable. The “Ensuring Patient Access and Effective Drug Enforcement Act of 2016” (P.L. 114-145) has severely limited the Drug Enforcement Administration’s (DEA) response to the opioid crisis.

In 2016, more than two million Americans had an addiction to prescription or illicit opioids. Since 2000, more than 300,000 Americans have died from overdoses involving opioids.

“In the midst of this deepening public health crisis – at a time when our nation needs every available weapon at its disposal to combat the opioid epidemic, the Act effectively strips the Drug Enforcement Administration of a mission critical tool, namely, the ability to issue an immediate suspension order against a drug manufacturer or distributor whose unlawful conduct poses an immediate danger to public health or safety,” reads the letter, sent late yesterday to leaders in the United States Senate and House of Representatives. “We urge you to repeal the Act so that the public is protected and drug manufacturers and distributors may be held accountable for their actions.”

The letter, signed by 44 attorneys general in the states, District of Columbia and the U.S. Virgin Islands, was coordinated by the National Association of Attorneys General (NAAG). State and territorial attorneys general have been fighting the opioid crisis over the years on multiple fronts, including law enforcement action such as lawsuits, investigations and settlements, and disrupting trafficking networks and closing pill mills.